Insider buying last 90 days
No open-market insider purchases were filed for INNV in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every INNV insider filing, plotted on the chart in Gekko.Open INNV in Gekko
NASDAQ: INNV
InnovAge (INNV) Stock Analysis & Forecast
Oct 12 close
$9.15+0.05 (+0.5%)
Gekko Brief
AI summaryOct 12 closeInnovAge reported fiscal 2026 results with revenue up 15.9% to $989.7 million and adjusted EBITDA reaching $94.6 million, alongside a GAAP net loss for the year despite a strong fourth quarter. Management also laid out a bigger fiscal 2027 growth plan and participated in the 2026 Wells Fargo Healthcare Conference, where CEO Patrick Blair and CFO Ben Adams discussed progress on the Program of All-Inclusive Care for the Elderly. Separately, a secondary offering priced 10 million shares at $9.25, with existing holders selling rather than the company issuing new stock.
INNV closed at $9.15, up 0.5%, sitting between its 50-day average of $10.31 and 200-day average of $8.80, with the one-month return at -14.9% and the three-month return at -21.2%, while the six-month return stands at 12.4% and the one-year return at 54%. The GekkoIndex reads 65.2, placing the stock in the Accumulation zone, down 4.5 over five days. Price sits 16.9% below Gekko Fair Value of $11.01.
InnovAge next reports earnings on 3 November 2026 after the close, 22 days away and inside a typical 20-trading-day holding window, with past reactions averaging 10% in absolute terms and five beats in the last eight quarters. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality from this point in the calendar has averaged a 14.9% move over the next 20 trading days across 5 years, rising in 4 of them. Consensus among 2 covering firms includes 1 buy and 1 hold, with a consensus target of $12.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
InnovAge price vs fair value
Close $9.15200-day averageGekko Fair Value $11.01
InnovAge quick facts
- Market cap
- $1.24B
- P/E ratio
- —
- Forward P/E
- 13.7
- EPS, TTM
- −$0.02
- Revenue, TTM
- $989.7M
- Profit margin
- -0.3%
- Dividend yield
- —
- Beta
- 0.15
- Volume
- 295,773 avg 893,019
- 1-year return
- +54.0%
- Typical daily move
- ±4.8%
- Typical 20-day move
- ±10.2%
- 50-day average
- $10.31
- 200-day average
- $8.80
- Next earnings
- Nov 3 after close
- Shares outstanding
- 136.5M
InnovAge swing-trade checklist
InnovAge scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $9.15 sits between the 50-day ($10.31) and 200-day ($8.80) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
65.2, Accumulation
Reading 65.2 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
16.9% below
Price is 16.9% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+14.9% on average
From this point in the calendar, the next 20 trading days averaged +14.9% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
InnovAge stock chart and price history
InnovAge closed at $9.15 on Oct 12, 2026, +54.0% over the past year, inside a 52-week range of $3.94 to $12.64.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −14.9%
- 3 months
- −21.2%
- 6 months
- +12.4%
- 1 year
- +54.0%
The full INNV chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open INNV in Gekko
Follow InnovAge through every session
Put INNV on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track INNV in GekkoFree for 7 days. No credit card required.
About InnovAge
InnovAge coordinates medical care and related support for older adults who wish to remain in their own homes rather than move into institutional settings. Working through the Program of All-Inclusive Care for the Elderly framework, the company brings together a wide mix of services, including in-home visits for skilled and personal care, and center-based offerings such as primary care, physical and occupational therapy, speech therapy, dental and mental health treatment, meals, and group activities. It also arranges transportation for participants traveling to its centers or to outside medical appointments, along with ongoing care management.
The company organizes its operations around participants it serves directly, rather than through separate product lines, and runs PACE centers across several states, including Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia, all within the United States.
InnovAge is headquartered in Denver, Colorado, and traces its founding back to 1989, having previously operated under the name TCO Group Holdings before adopting its current name in January 2021. Its shares are listed on the NASDAQ under the ticker INNV.
- Listed
- NASDAQ
- Sector
- Technology services
- Industry
- Packaged software
- Website
- innovage.com
InnovAge GekkoIndex: the smart money zone
InnovAge’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 65.2, in the Accumulation zone, down 4.5 points over five sessions.
65.2Accumulation
Down 4.5 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 36 | +1.6% | −6.9% | ||
| Accumulation (current zone) | 244 | +0.7% | +3.5% | ||
| Neutral | 362 | +0.5% | +3.2% | ||
| Distribution | 37 | +2.9% | +8.2% | ||
| Selling | 3 | Too few readings yet | |||
Average INNV share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the INNV price, zone by zone.Track INNV in Gekko
Is InnovAge stock overvalued? Gekko Fair Value
InnovAge trades 16.9% below Gekko Fair Value of $11.01, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what InnovAge shares are worth, recalculated every trading day.
$11.01
Gekko Fair Value, Oct 10, 2026
16.9% Undervalued
At the end of Aug 2026 the price was 3.8% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open INNV in Gekko
InnovAge insider and Congress trading
No open-market insider purchases were filed for InnovAge, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in INNV were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for INNV, plotted on the chart in Gekko.Open INNV in Gekko
Buybacks
InnovAge has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $1.14M
- As a share of market cap
- 0.09%
From company filings.
InnovAge earnings: next date and track record
InnovAge reports on Nov 3, 2026, after the close (22 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected after the close, 22 days away
- EPS estimate
- $0.09
- Revenue estimate
- $257.2M
5 of 8reports beat the EPS estimate
±10%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Feb 3, 2026 AI summary
- What they said
- InnovAge reported Q2 2026 results with revenue of $239.7 million, center-level contribution margin of $52.8 million, Adjusted EBITDA of $22.2 million, and net income of $11.8 million. H1 2026 Adjusted EBITDA was $39.8 million, surpassing the full-year 2025 Adjusted EBITDA of $34.5 million, and the company achieved an adjusted EBITDA margin of 9.2% in Q2—the first time it hit its intermediate-term target of 8-9%. Management attributes the margin strength to disciplined execution across clinical, operational, and financial initiatives and a rebuilt foundation after prior challenges. Revenues grew 14.7% year-over-year to $239.7 million driven by more member months and higher capitation rates, with census of about 8,010 participants across 20 centers as of 12/31/2025. The company highlighted ongoing initiatives around Medicaid redeterminations, enrollment processing, and a shift to in-house pharmacy to improve cost structure, though there are near-term headwinds including seasonality in enrollment (Q3 is typically softer) and a tougher flu season. In the Q&A, management and investors discussed margin progression for the back half, the impact of rate changes (including v28) and frailty adjustments, enrollment dynamics, and strategies to improve patient experience and reduce voluntary disenrollment. The overall sentiment reflects cautious optimism, supported by solid first-half performance and progress in addressing regulatory and enrollment-related challenges, but with near-term seasonality and program changes creating some uncertainty.
- Guidance
- Guidance highlights: management notes that they achieved the 8-9% Adjusted EBITDA margin target in Q2 for the first time and intends to maintain progress toward that target over the two- to four-year horizon. They expect Q3 to be softer due to open enrollment timing and the bad flu season, followed by a normalization in Q4. They are actively monitoring Medicaid redeterminations and rate changes (v28), and they have recalibrated the forecast through a two-quarter reforecast to incorporate latest thinking. No specific full-year numeric guidance was issued beyond reaffirming the margin-target trajectory and the ongoing financial and operational initiatives.
- Risks flagged
- Key risks discussed include: (1) enrollment volatility related to Medicaid redeterminations and open enrollment timing, (2) seasonality effects (Q3 softness) and the impact of a severe flu season, (3) changes in Medicaid and Medicare capitation rates and rate adjustments (v28) and the associated frailty scoring adjustments, (4) regulatory actions and federal budget changes, (5) delays or variability in enrollment processing by states, and (6) ongoing investment requirements to sustain a regulated, investment-intensive care model. The forward-looking statements are subject to risks and uncertainties.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Feb 3, 2026 | $0.08 est $0.04 | $239.7M est $228.4M | +36.5% |
| Sep 9, 2025 | −$0.01 est −$0.01 | $218.1M est $219.8M | +3.0% |
| May 5, 2025 | $0.02 est −$0.01 | $218.1M est $219.8M | −9.5% |
| Feb 4, 2025 | −$0.10 est −$0.01 | $209.0M est $214.1M | −4.8% |
| Nov 5, 2024 | −$0.04 est −$0.04 | $205.1M est $203.3M | +6.8% |
| Sep 10, 2024 | −$0.01 est −$0.03 | $199.4M est $191.5M | −8.0% |
| May 7, 2024 | −$0.04 est −$0.03 | $193.1M est $190.6M | −1.4% |
| Feb 6, 2024 | −$0.01 est −$0.03 | — | −9.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
InnovAge stock forecast and analyst price targets
Analysts’ average 12-month price target for InnovAge is $12.00, +31.1% from the last close, from 2 firms rating the stock in the last 90 days.
$12.00consensus 12-month target, +31.1% from the last close
Each firm’s latest rating in the last 90 days: 2 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 9 | William Blair | — | — |
| Sep 9 | KeyBanc | $14 | +53.0% |
| Aug 21 | KeyBanc | $13 | +42.1% |
+3.5%average 20-day move after past Accumulation readings
+14.9%average move over the next 20 trading days in the last 5 years
±4.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
InnovAge seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, InnovAge averaged +14.9% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +7.7% | 4 of 5 |
| Next 10 trading days | +4.7% | 4 of 5 |
| Next 15 trading days | +5.4% | 3 of 5 |
| Next 20 trading days | +14.9% | 4 of 5 |
| Next 30 trading days | +11.5% | 3 of 5 |
For scale, INNV’s typical 20-trading-day move in either direction is about 10.2%.
InnovAge market cap and key statistics
InnovAge’s market cap is $1.24B and revenue of $989.7M over the last twelve months.
Valuation
- Market cap
- $1.24B
- Forward P/E
- 13.7
- EPS, TTM
- −$0.02
- Gekko Fair Value
- $11.01
Trading
- Volume
- 295,773
- Avg volume, 20 days
- 893,019
- 52-week high
- $12.64
- 52-week low
- $3.94
- Shares outstanding
- 136.5M
Financials
- Revenue, TTM
- $989.7M
- Profit margin
- -0.3%
- Return on equity
- -0.3%
- Quarterly earnings growth, YoY
- −87.8%
Risk and income
- Beta
- 0.15
- Typical daily move
- ±4.8%
- Typical 20-day move
- ±10.2%
InnovAge stock news this week
Coverage of InnovAge this week reads neutral: 2 positive, 3 neutral and 0 negative headlines.
- InnovAge : Participates at 2026 Wells Fargo Health Conferencewww.marketscreener.com, Oct 8
- InnovAge stock carries a bigger fiscal 2027 growth planAD HOC NEWS, Oct 7
- Argent Capital Management LLC Acquires 74,112 Shares of InnovAge Holding Corp. $INNVDefense World, Oct 6
- InnovAge stock posts 15.9 percent revenue growth for fiscal 2026AD HOC NEWS, Oct 5
- InnovAge prices 10 million shares at USD 9.25 for InnovAge stockAD HOC NEWS, Oct 5
- INNV 10-Q Filings - InnovAge Holding Corp. SEC 10-QStock Titan, Oct 5
InnovAge peers
InnovAge’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| MSFTMicrosoft | Neutral | 21.7% above |
| PLTRPalantir Technologies | Distribution | 22.3% above |
| ORCLOracle | Neutral | 24.3% below |
| PANWPalo Alto Networks | Neutral | 21.6% above |
| CRWDCrowdStrike | Neutral | 23.7% above |
| CRMSalesforce | Neutral | 3.6% below |
A peer links to its own page where one exists.
InnovAge stock FAQ
What is InnovAge’s market cap?
InnovAge’s market cap is $1.24B at the Oct 12, 2026 close of $9.15, with 136.5M shares outstanding.
What is the InnovAge stock forecast?
The consensus analyst 12-month price target for InnovAge is $12.00, +31.1% from the last close. Of the 2 firms that rated the stock in the last 90 days, 1 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is InnovAge stock overvalued or undervalued?
On Gekko’s estimate InnovAge is undervalued: the Oct 12, 2026 close of $9.15 is 16.9% below Gekko Fair Value of $11.01. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does InnovAge report earnings next?
InnovAge is expected to report on Nov 3, 2026, after the market closes (22 days away). Analysts expect earnings of $0.09 per share on revenue of $257.2M. InnovAge beat the earnings estimate in 5 of its last 8 reports, moving 10% on average across the report.
What is InnovAge’s 52-week high and low?
InnovAge’s 52-week high is $12.64 and its 52-week low is $3.94; it closed at $9.15 on Oct 12, 2026, +54.0% over the past year.
Is InnovAge stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See InnovAge the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.